Aug 9, 2024, 02:14
T-DXd in HER2 – Expressing Biliary Tract Cancer
Yakup Ergün, Medical Oncologist at Batman World Hospital, shared on X about a recent paper by Akihiro Ohba et al. titled “Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial” published in Journal Of Clinical Oncology.
Authors: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda et al.
“T-DXd in HER2 – Expressing Biliary Tract Cancer (HERB: NCCH1805):
Single-Arm, Phase II Trial
32 pts previously treated, 5.4mg/kg
ORR
HER2+36.4%
HER2-Low12.5%
ILD 25% (G5 6%)
ILD requires careful monitoring and early intervention!”
Source: Yakup Ergün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14